compounding glp 1 Patients struggle as compounded GLP-1 access rapidly shrinks Compounded GLP-1 ban: What providers

A prespecified secondary analysis of SELECT participants without diabetes showed that semaglutide reduced the composite kidney endpoint by 22% (86), with 75% of participants on RAAS blocker therapy at baseline

H.HanssonC.BergquistF.NissbrandtH.SkibickaK

They help regulate appetite, blood sugar, and metabolic signaling rather than forcing weight loss through stimulation or appetite suppression alone

This may be partly mediated by improvements in weight loss and glucose control

[DOI] [PubMed] [Google Scholar] 74.Klein S, Gastaldelli A, Yki-Jarvinen H & Scherer PE Why does obesity cause diabetes

Last month, a Novo spokesperson confirmed to BioSpace that the pharma had filed for approval for oral Wegovy